Search bioRxivSearch

Biology subjects

Aller, S.

Publications and source records attributed to Aller, S..

2 recordsLinked to original sources

Allosteric Role of Substrate Occupancy Toward the Alignment of P-glycoprotein Nucleotide Binding Domains

P-glycoprotein (Pgp) is an ATP-binding cassette transporter that eliminates toxins from the cell but causes multidrug resistance in chemotherapies. The crystal structures of Pgp revealed drug-like compounds bound to an inward-facing conformation in which the energy-harnessing nucleotide binding domains (NBDs) were widely separated with no interfacial interaction. Following drug binding, inward-facing Pgp must transition to an NBD dimer conformation to achieve ATP binding and hydrolysis at canonical sites defined by both halves of the interface. However, given the high degree of flexibility shown for this transporter, it is difficult to envision how NBDs overcome entropic considerations for achieving proper alignment in order to form the canonical ATP binding site. We explored the hypothesis that substrate occupancy of the polyspecific drug-binding cavity plays a role in the proper alignment of NBDs using computational approaches. We conducted twelve atomistic molecular dynamics (MD) simulations (100-300 ns) on inward-facing Pgp in a lipid bilayer with and without small molecule substrates to ascertain effects of drug occupancy on NBD dimerization. Both apo- and drug-occupied simulations showed NBDs approaching each other compared to the crystal structures. Apo-Pgp reached a pseudo-dimerization in which NBD signature motifs for ATP binding exhibited a significant misalignment during closure. In contrast, occupancy of three established substrates positioned by molecular docking achieved NBD alignment that was much more compatible with a canonical NBD dimerization trajectory. Additionally, aromatic amino acids, known to confer the polyspecific drug-binding characteristic of the internal pocket, may also govern polyspecific drug access to the cavity. The enrichment of aromatics comprising the TM4-TM6 portal suggested a preferential pathway over the aromatic-poor TM10-TM12 for lateral drug entry from the lipid bilayer. Our study also suggested that drug polyspecificity is enhanced due to a synergism between multiple drug-domain interactions involving 36 residues identified in TM1, 5, 6, 7, 11 and 12.\n\nAuthor SummaryP-glycoprotein (Pgp) is an active drug pump known to cause clinical multi-drug resistance. The static atomic structure of Pgp was determined by trapping an inward-facing conformation bound to small molecule substrates by crystallization, however the effect of substrates on Pgp dynamics following binding is poorly understood. In this study, six apo-Pgp and six drug-occupied Pgp were simulated using unconstrained atomistic molecular dynamics (MD) for 100-300 ns. We demonstrate an allosteric communication of drug binding \"from the top down\", that is from the TMDs to the NBDs that promotes NBD alignment and trajectories that favor canonical ATP binding. Other analyses suggested that aromatic amino acids in both the central drug-binding cavity and the \"front portal\" (TM4/TM6) confer polyspecific recognition. Additionally, comparison of the thermal B-factors between the experimental measurement and MD simulation indicated that different physical and chemical environments (temperature, in surfo vs. in meso, solution compositions) only alter the regional scales of thermal fluctuations but not the patterns of these motions. Lastly, DCCM and normal mode analyses were used to decipher thermal motions and the motion correlations between various domains in Pgp, allowing us to propose a substrate allosteric mechanism and an energy conservation mechanism during the catalytic cycle.

biophysics

Integrated Human-Virus Metabolic Modelling Predicts Host-Based Antiviral Targets Against Chikungunya, Dengue and Zika Viruses

Current and reoccurring viral epidemic outbreaks such as those caused by Zika virus illustrate the need for rapid development of antivirals. Such development would be immensely facilitated by computational approaches that can provide experimentally testable predictions for possible antiviral strategies. A key factor that has not been considered fully to date in the study of antiviral targets is the high dependence of viruses to their host metabolism for reproduction. Here, we focus on this dependence and develop a stoichiometric, genome-scale metabolic model that integrates human macrophage cell metabolism with the biochemical demands arising from virus production. Focusing this approach to currently epidemic viruses Chikungunya, Dengue and Zika, we find that each virus causes specific alterations in the host metabolic flux towards fulfilling their individual biochemical demands as predicted by their genome and capsid structure. Subsequent analysis of this integrated model allows us to predict a set of host reactions, which when constrained can inhibit virus production. We show that this prediction recovers most of the known targets of existing antiviral drugs, while highlighting a set of hitherto unexplored reactions with either broad or virus specific antiviral potential. Thus, this computational approach allows rapid generation of experimentally testable hypotheses for novel antiviral targets within a host.\n\nSIGNIFICANCE STATEMENTA key challenge in combatting any new and emerging virus outbreaks is rapid drug development. In particular, generation of experimentally testable hypotheses through computational approaches is mostly lacking. Here, we address this gap by developing host-virus metabolic models for three viruses that cause current (or previously) epidemic viral outbreaks. We develop viral biomass functions using information from their genomes and physical structure, and incorporate these within a genome-scale metabolic model of human macrophage cells. The resulting integrated model allows us to predict host reactions, which when blocked, stop the system from attaining optimal viral production. These predictions recover currently known antiviral targets within human cells, and highlight a set of new reactions that are hitherto not explored for antiviral capacity.

systems biology